NewAmsterdam Pharma (NAMS) Capital Expenditures (2023 - 2026)

NewAmsterdam Pharma has disclosed Capital Expenditures across 4 years of filings, most recently posting $38000.0 for Q1 2026.

• Capital Expenditures for Q1 2026 came in at $38000.0, up 137.5% year-over-year; the trailing twelve-month figure through Mar 2026 was $268000.0 (down 11.55% YoY), and the FY2025 annual result was $246000.0, down 63.39% from the prior year.
• Capital Expenditures came in at $38000.0 for Q1 2026 at NewAmsterdam Pharma, down from $100000.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $385000.0 in Q1 2024 to a low of $3000.0 in Q4 2023.
• The 4-year median for Capital Expenditures is $38000.0 (2026), against an average of $75384.6.
• Across the five-year window, Capital Expenditures surged 5400.0% in 2024 and slumped 95.84% in 2025, its largest moves.
• NewAmsterdam Pharma's Capital Expenditures stood at $3000.0 in 2023, then changed by 0.0% to $3000.0 in 2024, then jumped by 3233.33% to $100000.0 in 2025, then plunged by 62.0% to $38000.0 in 2026.
• The last three Capital Expenditures figures came in at $38000.0 (Q1 2026), $100000.0 (Q4 2025), and $42000.0 (Q3 2025), per Business Quant data.